mbi

Our Portfolio 4 Zika Diagnostics

6 Peak Performance

8 Mobile Biosensing Diagnostics

10 Prospiria

12 Coagulation Reference Laboratory

14 Population Health Management

12 Coagulation Reference Laboratory

Medical BranchInnovations, Inc.

A Subsidiary of

The University of TexasMedical Branch at

Galveston

medical branch innovationsdevice

ana

lytics

diversified

investment

mob

ile health

biotechnolog

ies

developm

ent

partnerships

dia

gnostics

valid

ation

disruptive

ag

ile

dat

a

vers

atilit

y

spon

sors

hip

virtu

aliz

atio

n

tech

nolo

gie

s

entre

pre

neur

ial

com

mer

cia

lizat

ion

dig

ital h

ealth

life

scie

nces

optim

izatio

n

treat

men

t

nim

ble

14 Population Health Management

Zika DiagnosticsZika DiagnosticsCOMPANYThe company leverages existing IP to develop and commercialize novel Zika virus diagnostic point-of-care (POC) products and services. The new company will focus on the development and commercial use of antibodies against non-structural viral proteins (that are generated only during viral replication) for the detection of replicating Zika virus and the prevention of associated microcephaly in utero.

INDUSTRYInfectious disease tests are among the most dynamic in the in vitro diagnostics (IVD) industry. Occasional explosive market growth in the infectious disease test market can occur with the emergence of a new disease

threat or acceptance of a new routine screening procedure. Infectious diseases also are the frequent targets of novel technology applications, including PCR-alternative molecular amplification methods, next-generation sequencing, microarrays, and mass spectrometry. With new technologies and a growing demand for tests due to increased cases of infection, the market for infectious disease testing is expected to grow from $16.8 billion in 2015 to $20.9 billion in 2020.

VALUE PROPOSITIONProvision of fast, accurate, point-of-care and in-field testing of non-structural Zika viral protein targets for the detection of replicating Zika virus

5

S

W

O

TSTRENGTHS

World-renowned experience in infectious disease

Galveston National Laboratory

Existing IP

WEAKNESSES

Complicated development work

Unknown manufacturing requirements

OPPORTUNITIES

Pending Zika epidemic in the Americas

Existing relationship with Brazilian government THREATS

Lack of established manufacturing infrastructure

MARKET STRATEGYThis opportunity leverages the existing expertise at the University of Texas Medical Branch/Galveston National Laboratory (UTMB/GNL) to develop the antibodies to non-structural viral protein targets. POC testing will be developed and clinically validated in Brazil through existing partnerships between the Brazilian government and UTMB. Validation in the Brazilian health care system will create an instant market for the diagnostic testing needs of Brazil and neighboring countries. The market is forecast to expand with predicted proliferation of the Zika virus.

MARKET DEMANDAn epidemic of the Zika virus will create the demand for testing women of childbearing age throughout the Americas.

ELEVATOR PITCHZika screening for expectant mothers

PRODUCTS/SERVICES• Athometestkits(lateralflowdevices)• In-fieldtestkits(mobiledetection)• POCtestingkitsandinstrumentation• Testingservicesandinterpretativeanalysis

TARGET MARKETS• FemalepopulationsthroughouttheAmericas• Hospitals,clinics,healthdepartments• Researchandacademicinstitutions

COMPETITORS• Roche• BiocanDiagnostics• Chembio• ATFirst

BRAND PILLARS• UTMB• GalvestonNationalLaboratory• RenownedInfectiousDiseaseExpertise

VMPF Value:Fast,accurate,andactivevirusspecificMoney Making Capability: Diagnostic screens for women and affected populations Problem-Solving: Positive differentiation from other flavivirusesFit: Leverage institutional expertise in viral transmission and detection along with key government relationships within the Brazilian government for test validation

COMPANYThe University of Texas Medical Branch (UTMB) currently partners with NASA and private venture aerospace companies to assess and train astronauts, cosmonauts, and other aerospace professionals to achieve peak physical and mental condition in order to qualify and participate in space-related missions such as trips to the International Space Station (ISS). In order to achieve peak wellness, astronauts, cosmonauts, and other aerospace professionals work with a cadre of healthcare professionals, mental health professionals, and trainers to assess, analyze, and improve a plurality of assessment components, including but not limited to nutrition, BMI, sleep, physical fitness, and mental cognition. This company intends to develop and market a variety of digital adaptive wellness applications for the common person to achieve peak wellness through a proven system which has been validated in real aerospace programs.

INDUSTRYThe global sport and fitness applications market is exploding with a predicted CAGR of 23.78 percent through 2018. One of the key factors contributing to this market growth is the cost-effective nature of apps. The global sport and fitness apps market is also experiencingmarked growth. However, the difficultyof navigating the apps online could pose a challenge to the growth of this market.

VALUE PROPOSITIONThe adaptive wellness applications are the only health and wellness programs that have been validated within NASA and aerospace companies.

MARKET STRATEGYThe company will complete the adaptive wellness applications with insights from NASA and other aerospace partners. Subsequently, exclusive and non-exclusive licenses will be available. If no exclusive license is granted, the company will assess potential

partnerships with digital wearable vendors. Straight-to-consumer products such as preventive health and wellness programs can also be evaluated for potential sponsorship by insurers or private companies.

MARKET DEMANDThe global health and fitness mobile app market was worth about $4 billion in 2014; it is estimated to grow to $26 billion by 2017.

ELEVATOR PITCHBecome as mentally and physically fit as an astronaut

PRODUCTS/SERVICES• Adaptivewellnessapplications• eBooks• Adaptivewellnesssimulationplatforms• Customizedwellnessservices

TARGET MARKETS• Aerospacecompanies• Healthandfitnesscompanies• AppleandSamsung(IOSandAndroid)• Healthandwellnessenthusiasts

COMPETITORS BRAND PILLARS• FitBit •UTMB• Garmin •NASA• Jawbone •Inventors • Azumio •PrivateAerospace

• EndomondoApS Companies • FitnessKeeper

VPMF Value: Validated aerospace wellness trainingProblem-Solving: Sustained healthMoney Making Capability: Low cost app development for multiple product linesFit: The adaptive wellness program has been developed internally at UTMB: external commercialization is the natural next step

Peak Performance

7

S

W

O

TSTRENGTHS

Inventor expertise and experience

A�liation with �agship medical center

Established aerospace industry partners

WEAKNESSES

Complicated development work

Unknown manufacturing requirements

OPPORTUNITIES

Leverage existing aerospace partnerships to test and launch

product

Exclusive development and general population product o�erings

THREATS

Extremely crowded �tness and health market

Product and service chum

S

W

O

TSTRENGTHS

Existing patent portfolio

Academic reputation and experience of founders

and advisors

Clinical validation

WEAKNESSES

Lack of established manufacturing infrastructure

OPPORTUNITIESPotential partnerships

with established in vitro diagnostic companies

Early stage product development & testing

at KSU Veterinary School

THREATS

Broad range of established in vitro diagnostic testing

technologies and standards

Timeline for FDA regulatory approval

Mobile Biosensing DiagnosticsCOMPANYMobile Biosensing Diagnostics (MBD) was established through collaboration between the University of Texas Medical Branch (UTMB) and Kansas StateUniversity (KSU) to advance in vitro diagnostics (IVD) via an integrated mobile computing-based optical microfluidic biosensing platform. MDB offers novel capabilities that facilitate development and commercialization of new mobile biosensor detection and analysis.

INDUSTRYThe global IVD market is consolidated in nature, with top five companies accounting for nearly 55%–60% market share. The principals in this industry have built a strong market position over the years by focusing on innovative solutions and expanding their geographic presence in emerging markets in order to widen revenue streams.

VALUE PROPOSITIONMBD provides a low cost, highly accurate, highly mobile point-of-care (POC) diagnostic platform that incorporates detection of genome, proteome, and secretome targets from the same sample.

MARKET STRATEGYMBD will be positioned to leverage its extensive IP portfolio to develop a variety of licensing and sub-licensing strategies. MBD will also take advantage of multiple product segmentations to generate revenue throughout the development continuum. The first product will serve non-regulated and limited regulatedmarketswhileFDAapprovalactivitiesandmilestones are met for heavily regulated markets.

MARKET DEMANDGlobal in vitro diagnostics market is estimated to reach $75.1 billion by 2020.

ELEVATOR PITCHPoint-of-care diagnostics via smart phone

PRODUCTS/SERVICES• For-research-onlytestkits• Direct-to-consumerkits(23andMemodel)• Veterinaryin vitro diagnostic kits and testing services• Humanin vitro diagnostic test kits and testing services• POCdiagnosticinstrumentationand consumables

TARGET MARKETS• Academiclabs•Individualsfordiagnostic/non-diagnostic

purposes• Veterinarymedicine•Hospitalsanddiagnosticlabs•Retailpharmacies

COMPETITORS•RocheDiagnostics•Abbott•BD•ThermoFisherScientific•Qiagen

BRAND PILLARS•UTMB•KSU•RenownedInventors

VPMF Value: Low cost, portable, Limit of Detection (LOD)Problem-Solving: Multiplexing across multiple starting materialsMoney Making Capability: Multiple markets targeted around development and regulatory milestonesFit: Leveraging institutional knowledge and experience

9

COMPANYProspiria, Inc. has developed and tested PoET™, anoninvasive, optoacoustic device that determines precisely where an endotracheal tube is located within the trachea. PoET™ has been successfullytested in animal models, infants, and adults. The entire procedure with the clinical prototype requires only 15 to 30 seconds and does not require interruption of mechanical ventilation or movement of a patient. The operating principle is optoacoustic, in which a pulsed laser light generates an ultrasound signal, which, because of the high spatial resolution of ultrasound, provides highly accurate information regarding the position of an endotracheal tube within the trachea. Prospiria has developed decision-assist software to guide clinicians in assessing the position of endotracheal tubes.

INDUSTRYThe intubation industry is dominated by low cost disposable intubation equipment, with major manufacturing occurring in Asia. Endoscopictechnologies are sometimes used to help in the intubation process. The use of optoacoustic technology is a “Blue Ocean” opportunity for market development.

VALUE PROPOSITIONPoET™ can reduce, perhaps nearly to zero, thenumber of chest radiographs required to determine endotracheal tube position immediately after intubation or subsequently during care. Reduction of chest radiographs is particularly important in infants and children because of the need to limit radiation exposureinthisvulnerablepopulation.PoET™canalso

Prospiria

11

S

W

O

TSTRENGTHS

Inventor expertise and experience

A�liation with �agship medical center WEAKNESSES

Experience in 510K regulatory clearance

OPPORTUNITIES

Multiple clinical partnerships for testing

Natural �t for industrial partner expansion THREATS

Endoscopic technologies

Better intubation training

markedly reduce the incidence of unrecognized right mainstem intubation and associated atelectasis and also reduce the incidence of accidental extubation.

MARKET STRATEGYProspiria will seek major venture funding or partnership with a manufacturer. Potential partners include manufacturers of endotracheal tubes, manufacturers of mechanical ventilators, and manufacturers of critical care and anesthesiology monitors. The marketing strategy depends on whether Prospiria has a major manufacturing partner or is a freestanding corporation. If Prospiria has a major manufacturing partner, the partner will manage marketing of PoET™. If Prospiria is freestanding,contract vendors who work through group-purchasing organizations will manage marketing. In either case, a major part of the marketing effort will consist of demonstration of the device for influential clinicians and sponsorship of research to demonstrate the value of the technology and limited regulated marketswhileFDAapprovalactivitiesandmilestonesare met for heavily regulated markets. The marketing effort will consist of demonstration of the device for influential clinicians and sponsorship of research to demonstrate the value of the technology and limited regulatedmarketswhileFDAapprovalactivitiesandmilestones are met for heavily regulated markets.

MARKET DEMANDCurrent market size of tracheal intubation is estimated at $3 billion annually (including approximately 2

million ICU intubations), with 13% of the procedures defined as difficult due to known complications.

ELEVATOR PITCHAccurate and safe intubation in seconds

PRODUCTS/SERVICES• PoET™

TARGET MARKETS• HospitalERsandEMTs• Urgentcare• Medicaltransport

COMPETITORS • Hamilton • Hayek • O-Two

BRAND PILLARS•UTMB•RenownedInventor

VPMF Value: Reduces errors during intubation that lead to injury and repeated proceduresProblem-Solving: Non-invasive assistance for endotracheal tube positioningMoney Making Capability: Ancillary instrumentation for intubation/ventilation equipment (safety feature/time savings)Fit: Leverage existing institutional expertise at UTMB

12

Coagulation Reference LaboratoryCOMPANYThe Coagulation Reference Laboratory (CRL) conducts laboratory testing in support of diagnostic services for disorders that result in excess bleeding or the formation of blood clots, including:•HeartAttack•Stroke•PulmonaryEmbolism•DeepVeinThrombosis•LiverDiseaseIn addition to testing, the CRL provides interpretive services that are specific to the patient for all cases.

INDUSTRYMany healthcare professionals are unaware of the various options available to control bleeding in patients and how to monitor patients taking anticoagulants other than warfarin (such as Pradaxa, Xarelto,andEliquis).Giventhatasignificantsegmentof the population experiences issues with bleeding or clotting, there is a substantial need for laboratories to provide test results and inform clinical decisions for such patients.

VALUE PROPOSITIONClinical laboratories equipped to assist physicians in

selecting the correct diagnostic blood tests and in personalizing the interpretation of blood results are extremely valuable in today’s healthcare industry. Despite demand, however, availability of and accessibility to these services is very limited. Because of this gap between demand and supply, physicians must continue to guess which coagulation tests to order for their patients and which treatments to apply when abnormalities are discovered. This proposal calls for the development of an enterprise that would make available in-depth coagulation testing and personalized interpretation of results, leading to much more precise and effective treatments for patients.

MARKET STRATEGYOnly two specialized coagulation laboratories in the commercial sector exist. Our strategy is to partner, through partial acquisition of Louisiana Coagulation Laboratory (LCL) with plans for expansion into two additional locations across the country. This strategy builds upon an existing infrastructure with an active book of businesses while leveraging the reputations of the principals at CRL/UTMB and LCL to offer enhanced testing and interpretative services across a diverse geographical area.

S

W

O

TSTRENGTHSWorld-renowned

experience in coagulation

A�liation with �agship medical center

Business aligns with healthcare trends

WEAKNESSES

Innovative business model may disrupt current

established laboratory models

OPPORTUNITIES

Demand for expert interpretative services is high

Few competitors o�ering BOTH testing and interpretations

Testing expandable to di�erent disorders

THREATS

Established national testing entities

MARKET DEMANDIndependentLaboratory

Volume: 218,921,000

Payment:$2,543,872,515

TopHCPCScode#4 Prothrombin TG

Volume:38,739,680

Payment:$227,861,177

ELEVATOR PITCHTake the guessing out of testing

PRODUCTS/SERVICES• Coagulationtestingandinterpretative

services • Treatmentandadvancedtesting

recommendations• Peer-to-peerconsultations

TARGET MARKETS• IndependentSoloPractices• CriticalCareHospital• RuralEDsandHospitals• SmalltoMediumGroupPractices

COMPETITORS• QuestDiagnostics• LabCorpofAmerica

• Spectra• DaVita• SonicHealthcareUSANoneofferBOTHtestingandinterpretative

services with peer-to-peer consultation.

BRAND PILLARS•UTMB• LCL• MichaelLaposata,MD (Ranked #3 globally and #1 in the US by

Pathologist magazine)

VPMFValue: Testing and interpretation results in better patient outcomesProblem-Solving: Eliminates uncertainty ofdiagnostics and treatmentMoney Making Capability: Margin for testing to expense is very favorableFit: Leveraging pre-eminent expertise and experience of flagship medical center

Population Health ManagementCOMPANYThe University of Texas Medical Branch (UTMB) has developed and implemented a Population HealthManagement System (PHMS) that provides fullyintegrated health care solutions. As part of this multi-component PHMS, customizable dashboardshave been developed to collect, aggregate, and display health care related data to improve patient outcomes, communicate to key stakeholders, identify opportunities for process improvement, and monitor progress of patients and patient populations againstpre-setHEDIS(HealthcareEffectivenessDataand Information Set) national benchmark measures. The dashboards provide real-time and retrospective reports on disease prevention and management statistics, medication management, access-to-care statistics, specialty/hospital services tools, and telehealth encounter totals. The dashboards can be further customized for stratified comparison purposes. The PHMS incorporates a novelmeetingdocumentation efficiency management tool, which will helps reduce operational costs and achieve maximum operational efficiency by providing digital editing and document storage and distribution.

14

S

W

O

TSTRENGTHS

Existing IP

Academic reputation and experience of UTMB

Clinical & administrative validation

WEAKNESSES

Uncertainty in non-captivated

health care populations

OPPORTUNITIES

Protracted need by state and correctional systems

for such a system

THREATS

Political uncertainty around current and future ACA

and associated health care needs and requirements

INDUSTRYThe implementation of the Affordable Care Act (ACA), incentives and investments by the federal government, rapid rise in the aging populations, and the increase in chronic diseases are driving the market growth. Increased focus on value-based medicine and personalized medicine is expected to create an array of opportunities in the population health management market. The population health management market is segmented on the basis of component, delivery mode, and end-user. Based on component, the market is categorized into software and services. The software segment is expected to grow at the highest rate. Based on delivery mode, the market is segmented into web-based, on-premise, and cloud-based. The web-based segment has accounted for the largest share; however, the cloud-based segment is expected to be the fastest growing segment moving forward. Based on end-user, the market is segmented into healthcare providers, healthcare payers, employer groups, and government bodies. The healthcare providers segment has accounted for the largest share of the market; however, the employer groups segment is expected to be the fastest growing segment moving forward.

VALUE PROPOSITIONPHMS has been clinically and administratively validatedwithinUTMB.PHMShasaproventrackrecordofincreasingthe quality of care, access to care, and reduction in individual patient and overall healthcare costs.

MARKET STRATEGYThe initial focus will be sales and service to other correctional systems for health care quality, access, and cost determination and tracking purposes. Secondary focus will be sales and service to other captivated health care environments.

MARKET DEMANDThe population health market is expected to reach $31.63 billion by 2020 from $11.13 billion in 2015, at a CAGR of 23.2%.

ELEVATOR PITCHClinically validated population health management with proven health quality improvements and cost reduction capabilities

PRODUCTS/SERVICESPopulationHealthManagementSystem

• PHMSSoftwareToolsandDashboard• DocumentationSharingandEfficiencyTools• DataAnalyticsPlatform

TARGET MARKETS• Corrections• Assistedliving/skillednursingfacilities• Collegesanduniversities• Hospitalsandclinics

COMPETITORS• McKessonCorporation• VeriskHealth• HealthCatalyst• Allscripts• IBM• OptumHealth

BRAND PILLARS• UTMB

VPMF Value: Increased health care quality, access, cost, and efficiencyProblem-Solving: Validated system for health care metric data collection, reporting, and comparisonMoney Making Capability: Validated product and service expansion into other states and correctional systemsFit: Leverage existing institutional expertise at UTMB

medical branch innovationsdevice

ana

lytics

diversified

investment

mob

ile health

biotechnolog

ies

developm

ent

partnerships

dia

g-

nos-

valid

a-

tion

disrup

-tive

ag

ile

dat

a

vers

atilit

y

spon

sors

hip

virtu

aliz

atio

n

tech

nolo

gie

s

entre

pre

neur

ial

com

mer

cia

lizat

ion

dig

ital h

ealth

life

scie

nces

optim

izatio

n

treat

men

t

nim

ble

medical branch innovationsana

lytics

diversified

investment

mob

ile health

biotechnolog

ies

developm

ent

partnerships

dia

gnostics

valid

ation

disruptive

ag

ile

dat

a

vers

atilit

y

spon

sors

hip

virtu

aliz

atio

n

tech

nolo

gie

s

entre

pre

neur

ial

com

mer

cia

lizat

ion

dig

ital h

ealth

life

scie

nces

optim

izatio

n

treat

men

t

medical branch innovationsdevice

ana

lytics

diversified

investment

mob

ile health

biotechnolog

ies

developm

ent

partnerships

dia

gnostics

valid

ation

disruptive

ag

ile

dat

a

vers

atilit

y

spon

sors

hip

virtu

aliz

atio

n

tech

nolo

gie

s

entre

pre

neur

ial

com

mer

cia

lizat

ion

dig

ital h

ealth

life

scie

nces

optim

izatio

n

treat

men

t

nim

ble

medical branch innovationsana

lytics

diversified

investment

mob

ile health

biotechnolog

ies

developm

ent

partnerships

dia

gnostics

valid

ation

disruptive

ag

ile

dat

a

vers

atilit

y

spon

sors

hip

virtu

aliz

atio

n

tech

nolo

gie

s

entre

pre

neur

ial

com

mer

cia

lizat

ion

dig

ital h

ealth

life

scie

nces

optim

izatio

n

treat

men

t

alexander vo, ph.d.ahvo@utmb.edu

13

mbi